CoChat

Evidence of androgen action in endometrial and ovarian cancers

The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.

Abstract

Endometrial cancer (EC) and ovarian cancer are common gynaecological malignancies. The impact of androgen action in these cancers is poorly understood; however, there is emerging evidence to suggest that targeting androgen signalling may be of therapeutic benefit. Epidemiological evidence suggests that there is an increased risk of EC associated with exposure to elevated levels of androgens, and genetic variants in genes related to both androgen biosynthesis and action are associated with an increased risk of both EC and ovarian cancer. Androgen receptors (ARs) may be a potential therapeutic target in EC due to reported anti-proliferative activities of androgens. By contrast, androgens may promote growth of some ovarian cancers and anti-androgen therapy has been proposed. Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. This review considers the evidence that androgens may be important in the aetiology of EC and ovarian cancer with discussion of evidence for androgen action in normal and malignant endometrial and ovarian tissue.

Overview

Integrity signals

Registry

Crossref · 10.1530/erc-13-0551

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 155 references

Research works printed but not linked: 9

  1. 2008, NUCLEAR RECEPTOR SIGNALING, 6, 008e
  2. Horie, 1992, Human Reproduction, 7, 184, 10.1093/humrep/ · doi:10.1093/humrep/
  3. Li, 2003, Clinical Cancer Research, 9, 3667
  4. 2011, JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 16, 999
  5. 1996, HUMAN CELL, 9, 109
  6. 2013, INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS, 124, 1
  7. Rabban, 2005, The Journal of reproductive medicine, 50, 467
  8. Syed, 2001, Cancer Research, 61, 6768
  9. 2013, EMBO MOLECULAR MEDICINE, 5, 983

Cited by

Metadata

Authors
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K.
Affiliations
MRC Centre for Reproductive Health (GB)
Venue
Endocrine-Related Cancer
Published
2014-02-28
Volume
21
Issue
4
Pages
T203-T218
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2108865532
Cited by
73
References
154
Citations by year
2026: 4 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 11 · 2015: 4 · 2014: 2
FWCI
1.10
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Related Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
androgen action, endometrial cancer, ovarian cancer, androgen receptor, androgen signaling, androgen production, genetic variants, cancer risk, antiandrogen therapy, tumor progression, endometrium, ovary
MeSH terms
Androgen Antagonists, Androgens, Endometrium, Female, Humans, Ovarian Neoplasms, Ovary, Receptors, Androgen, Endometrial Neoplasms, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.